Pancreatic Cancer Research

ResearcherMoffitt Cancer CenterActive in the last 2 years

Eric K. Nakakura

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0007-3714-7072; OpenAlex author ID A5040025890. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
80
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 4 papers · 2025: 1 paper · 2026: 4 papers

Papers 16

  1. Impact of adjuvant chemotherapy among pathologic complete responders with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejso.2026.111955↗
  2. Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time Bias on Survival. Co-author DOI 10.1245/s10434-026-19829-1↗
  3. ASO Visual Abstract: Re-evaluating the Role of Neoadjuvant Chemotherapy in Early-Stage Pancreatic Ductal Adenocarcinoma: Unveiling the Impact of Immortal Time … Co-author DOI 10.1245/s10434-026-19921-6↗
  4. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  5. Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer. Co-author DOI 10.3390/cancers17020170↗
  6. Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer. Last author DOI 10.1245/s10434-024-15579-0↗
  7. ASO Author Reflections: Total Neoadjuvant Therapy with Chemotherapy Alone for Pancreatic Cancer? First author DOI 10.1245/s10434-024-15660-8↗
  8. Distinct Indications for Adjuvant Therapy in Resected Invasive Mucinous Cystic Neoplasms of the Pancreas Compared with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15841-5↗
  9. Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.3390/curroncol31090370↗
  10. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  11. Comparison of Tumor Regression Grading of Residual Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Chemotherapy Without Radiation: Would Fewer Tier-Stra… Co-author DOI 10.1097/pas.0000000000001152↗
  12. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  13. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  14. Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy? First author DOI 10.1002/jso.24375↗
  15. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  16. Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. Co-author DOI 10.6004/jnccn.2012.0073↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mohamed A. Adam · 7 shared papers, 2024–2026 · strength 1.67
  2. Adnan A. Alseidi · 7 shared papers, 2024–2026 · strength 1.67
  3. Kimberly Saunders Kirkwood · 6 shared papers, 2016–2026 · strength 1.01
  4. Sophia Hernandez · 3 shared papers, 2025–2026 · strength 0.82
  5. Andrew H. Ko · 9 shared papers, 2012–2026 · strength 0.75
  6. Amir Ashraf‐Ganjouei · 3 shared papers, 2024–2026 · strength 0.71
  7. Phoebe N. Miller · 2 shared papers, 2024 · strength 0.63
  8. Jane Wang · 3 shared papers, 2024–2025 · strength 0.60
  9. Amir Ashraf · 2 shared papers, 2026 · strength 0.58
  10. Ajay V. Maker · 3 shared papers, 2024 · strength 0.57
  11. Margaret A. Tempero · 8 shared papers, 2012–2024 · strength 0.57
  12. Brian G. Czito · 6 shared papers, 2012–2026 · strength 0.43
  13. Robert A. Wolff · 6 shared papers, 2012–2026 · strength 0.43
  14. Mokenge Peter Malafa · 6 shared papers, 2012–2026 · strength 0.43
  15. Brian Matthew Wolpin · 6 shared papers, 2012–2026 · strength 0.43
  16. Al B. Benson · 6 shared papers, 2012–2026 · strength 0.43
  17. Andrew M. Lowy · 5 shared papers, 2014–2026 · strength 0.41
  18. Vincent M. Chung · 5 shared papers, 2014–2026 · strength 0.41
  19. Elena Gabriela Chiorean · 5 shared papers, 2014–2026 · strength 0.41
  20. Noelle K. LoConte · 4 shared papers, 2017–2026 · strength 0.38
  21. Courtney L. Scaife · 4 shared papers, 2017–2026 · strength 0.38
  22. Jeffrey M. Hardacre · 4 shared papers, 2017–2026 · strength 0.38
  23. Dana Backlund Cardin · 4 shared papers, 2017–2026 · strength 0.38
  24. Mary E. Dillhoff · 4 shared papers, 2017–2026 · strength 0.38
  25. Christos K Fountzilas · 3 shared papers, 2019–2026 · strength 0.33

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.